134P - Applicable CT-guided percutaneous radiofrequency ablation (RFA) in the treatment of unresectable Lung Ground Glass Opacity (GGO)

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Thoracic Malignancies
Surgical Oncology
Radiation Oncology
Presenter Ying Wei
Citation Annals of Oncology (2017) 28 (suppl_2): ii28-ii51. 10.1093/annonc/mdx091
Authors Y.T. Wei
  • Radiology, Beijing General Hospital of PLA, 100853 - Beijing/CN



Radiofrquency ablation (RFA) is a locoregional therapeutic for variable unresectable malignancies and currently used for lung cancer (either primary or metastatic). It is minimally invasive and accurate for percutaneous RFA under CT guidance. This study was to investigate the safety and efficacy of RFA in the treatment of unresectable lung Ground Glass Opacity (GGO).


From June 2015 to June 2016 a total of 68 patients (29 males and 39 females with a median age of 46 y, range, 29-78 y) with 83 lesions (GGO) have been enrolled in this study. As approved by institutional review board, all patients were informed and signed the consent forms beforehand. All the preselected lesions were proven by needle biopsy under CT guidance percutaneously prior to the procedure. In total 60 malignancies were ultimately included and CT-guided percutaneous RFA was serially performed with pre-set power of 40-80w and ablation time of 12-25 min. Imaging follow-up served as evaluation method.


All of the procedures were performed to completion. There were 18 patients with pneumothorax postoperatively and of those 6 needed a closed thoracic drainage. 8 patients showed slight bleeding during the procedures. Follow-up CT scanning at 30-, 90-, and 180-day postoperatively have shown that 56 of 60 lesions turned consolidated and with volume diminished. 4 of 60 were without significant dimensional change at 30-day follow-up, 3 of the 4 with accentuation were detected on 90-day CT follow-up and needed a reoperation of RFA.


CT-guided percutaneous RFA is safe and effective. It offers good control and is well-tolerated as a viable option for unresectable GGO.

Clinical trial identification

Legal entity responsible for the study

Chinese PLA General Hospital


Chinese PLA General Hospital


The author has declared no conflicts of interest.